Ann L White
Affiliation: University of Southampton
- FcγRΙΙB controls the potency of agonistic anti-TNFR mAbsAnn L White
Antibody and Vaccine Group, MP88, Cancer Sciences Unit, Faculty of Medicine, Southampton University Hospital, Tremona Road, Southampton, SO16 0XA, UK
Cancer Immunol Immunother 62:941-8. 2013..Thus, modifying the A/I binding ratio of human IgG Fc can be used to optimise different types of therapeutic activity by enhancing cytotoxic or hyper-crosslinking function...
- Interaction with FcγRIIB is critical for the agonistic activity of anti-CD40 monoclonal antibodyAnn L White
Division of Cancer Sciences, Faculty of Medicine, University of Southampton, Southampton SO16 6YD, United Kingdom
J Immunol 187:1754-63. 2011..In conclusion, we demonstrate an essential cross-linking role for the inhibitory FcγRIIB in anti-CD40 immunostimulatory activity and suggest that isotype will be an important issue when optimizing reagents for clinical use...
- Ligation of CD11c during vaccination promotes germinal centre induction and robust humoral responses without adjuvantAnn L White
Tenovus Research Laboratory, Cancer Sciences Division, Southampton University School of Medicine, General Hospital, Southampton, UK
Immunology 131:141-51. 2010..They also point to an interesting role for CR4 on DC in triggering B cells during humoral immunity...
- Conformation of the human immunoglobulin G2 hinge imparts superagonistic properties to immunostimulatory anticancer antibodiesAnn L White
Cancer Sciences Unit, Faculty of Medicine, University of Southampton, Tremona Road, Southampton SO16 6YD, UK Electronic address
Cancer Cell 27:138-48. 2015..This provides the exciting opportunity to engineer clinical reagents with defined therapeutic activity regardless of FcγR expression levels in the local microenvironment. ..
- Fcγ receptor dependency of agonistic CD40 antibody in lymphoma therapy can be overcome through antibody multimerizationAnn L White
Antibody and Vaccine Group, Cancer Sciences Unit, University of Southampton Faculty of Medicine, Southampton SO16 6YD, United Kingdom
J Immunol 193:1828-35. 2014..These findings have important translational implications, as humans, unlike mice, do not have IgG that binds strongly to FcγRIIB; therefore FcγR-independent derivatives represent an attractive therapeutic option. ..
- Influence of immunoglobulin isotype on therapeutic antibody functionStephen A Beers
Antibody and Vaccine Group, Cancer Sciences Unit, University of Southampton, Faculty of Medicine, General Hospital, Southampton, United Kingdom
Blood 127:1097-101. 2016..Here we summarize how isotype dictates mAb activity and discuss ways in which this information can be used for the development of enhanced therapeutics. ..
- FcγRIIB as a key determinant of agonistic antibody efficacyAnn L White
Cancer Sciences Unit, Antibody and Vaccine Group MP88, Faculty of Medicine, Southampton University, Tremona Road, Southampton, SO16 6YD, UK
Curr Top Microbiol Immunol 382:355-72. 2014..In this review we highlight the key role of FcγRIIB in regulating agonistic mAb, detail the likely mechanism of action and propose new ways in which this information may be exploited therapeutically. ..
- CD11c provides an effective immunotarget for the generation of both CD4 and CD8 T cell responsesFernanda V V Castro
Tenovus Research Laboratory, Cancer Sciences Division, Southampton University School of Medicine, Southampton, UK
Eur J Immunol 38:2263-73. 2008..These results suggest that targeting antigen via CD11c offers a previously unappreciated strategy for vaccine development which, unlike most targets, delivers robust responses of both CD4 and CD8 T cells...